Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2020

View Archived Issues

Atherosclerosis, AD meet at the myelin

p53 loss leads to immune evasion

Karus Therapeutics initiates phase II study of KA-2507 in biliary tract cancer

Enrollment open in phase II study of MSTT-1041A or UTTR-1147A in COVID-19 pneumonia

Clinical data for novel non-D2-receptor-binding compound in patients with schizophrenia

DNA-encoded immunotherapies show efficacy in models of N. gonorrhoeae infection

First-in-human characterization of RPT-193

IRAK-2 is a therapeutic target in atopic dermatitis and psoriasis

AiCuris discovers HBV caspid assembly inhibitors

New SSAO inhibitors identified at Boehringer Ingelheim

Esteve patents voltage-dependent calcium channel subunit alpha2/delta-1 ligands

Merck & Co. identifies new LRRK2 inhibitors

New TYK2 inhibitors disclosed by Bristol-Myers Squibb

Germline ApoE variants affect melanoma trajectory

PEG10 found behind pathogenic mechanisms of mycosis fungoides

Phase III trial of efgartigimod in generalized myasthenia gravis meets primary endpoint

Chi-Med and BeiGene to study surufatinib and fruquintinib with tislelizumab for solid tumors

Synairgen's phase II trial begins dosing SNG-001 in home setting to treat COVID-19

Novartis begins phase II study of DFV-890 for COVID-19 pneumonia

Glenmark to begin phase III study of favipiravir with umifenovir in moderate COVID-19

Tavotek and Genmab partner to develop antibody for autoimmune and inflammatory conditions

Levels of cytokine LIGHT correlate with disease severity and mortality in COVID-19 ARDS study

Popular Stories

23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema
BioWorld
Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa...